
HLP003 Achieves Statistically Significant Phase 3 Efficacy with Sustained Benefits Through Week 12, Supporting Higher Development Success Probability
HLP003 beat placebo by 7.6 points on the MADRS depression scale at Week 6 and by 7.0 points at Week 12. AER raises its illustrative valuation to $20.00 per share and examines three treatment-related serious adverse events, confirmatory trial timing, and quarterly cash use.




